ENTERA BIO LTD. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $289.00K, a 95.94% decline year-over-year.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for fiscal 2025 was $150.00K, a 79.97% decline from fiscal 2024.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for fiscal 2024 was $749.00K.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for fiscal 2022 was $13.00K, a 96.89% decline from fiscal 2021.
- ENTERA BIO LTD. stock issued during period, value, stock options exercised for fiscal 2021 was $418.00K, a 514.71% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $289.00K 10-Q · filed 2026-05-08 | $289.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $150.00K 10-K · filed 2025-03-28 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $7.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $7.31M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $7.12M 10-Q · filed 2026-05-08 | $7.86M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $749.00K 10-K · filed 2025-03-28 |
| 2024-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | |
| 2024-06-30 | $555.00K 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2025-03-28 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $13.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $13.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $13.00K 10-Q · filed 2023-08-11 | |
| 2021-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $418.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $122.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $48.00K 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $227.00K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $68.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |